# TB-500 Research: Mechanism, Tissue Repair, and the Thymosin Beta-4 Evidence > TB-500 research, channel by channel: the actin-sequestration mechanism, wound, cardiac, neurological and angiogenesis findings, and where the fragment's human data drop out. Mechanism first, then the repair findings — each tagged to the molecule that produced it and the species it was measured in. ## Mechanism: Actin Sequestration and the LKKTETQ Motif The TB-500 mechanism of action is the actin-binding chemistry of the LKKTETQ motif it carries. Full-length thymosin beta-4 is the major intracellular G-actin sequestering peptide: it binds monomeric (globular) actin 1:1, holding a buffered pool of unpolymerized actin and regulating cytoskeletal dynamics, cell migration, and motility. X-ray crystallography of a gelsolin-domain-1-thymosin beta-4 hybrid bound to actin, solved to 2 Angstroms, established the structural basis: thymosin beta-4 forms a 1:1 complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization, with a WH2-type actin-interacting motif underlying the contact [1]. Earlier biochemistry had already defined the interaction of thymosin beta-4 with muscle and platelet actin, fixing its role as an actin-monomer reserve in resting cells [13]. The LKKTETQ segment inside TB-500 is that actin-binding core. What is *not* established is that the isolated 7-mer reproduces the full protein's downstream effects at the doses used in peptide research — controlled human trials of the fragment do not exist [5]. The mechanism is shared at the binding-motif level; the systemic behavior of fragment versus protein is an open question. ## What the Research Literature Reports Across animal and in vitro models, thymosin beta-4 and its actin-binding region have been studied for wound healing, tissue and muscle repair, angiogenesis, cardiac and neurological recovery, and hair growth. A consolidating review frames the through-line: thymosin beta-4 binds actin, promotes cell mobilization and migration, decreases myofibroblast number to reduce scarring, is released by platelets and macrophages after injury to limit apoptosis and inflammation, and promotes angiogenesis [5]. The register here is deliberate. Searches for TB-500 benefits return a long list of claimed effects; what the literature actually supplies is *reported research findings* about a peptide, not benefits promised to a reader. The strongest of them are reproducible animal results; the weakest are single-model observations. And almost all of them used full-length thymosin beta-4, which is why each finding below carries the molecule it belongs to. Human efficacy of the TB-500 fragment is unproven, and the human clinical data that does exist belongs to the full-length protein, not the fragment [5]. ## Wound-healing research In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, raised wound contraction by at least 11% by day 7, and increased collagen deposition and angiogenesis; as little as 10 picograms stimulated keratinocyte migration two- to three-fold [3]. A combined-effects rodent study reported concurrent angiogenesis, wound-healing, and hair-follicle effects from the same protein [11], and a dermal-healing review summarizes the broad skin-repair activity [12]. These are full-length thymosin beta-4 results in animals. The fragment's human wound-healing efficacy has not been demonstrated. ## Cardiac research In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt; after coronary artery ligation it upregulated ILK and Akt, enhanced early myocyte survival, and improved cardiac function [2]. A separate mouse study reported that thymosin beta-4 prevented cardiac rupture and improved function after myocardial infarction [14]. The cardiac picture is not uniformly positive, which is part of the honest record. Systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, and an early injectable acute-cardiac trial was withdrawn — so a presumed clinical pipeline overstates the current evidence. ## Neurological research In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 at 2, 12, or 18 mg/kg (started 24 hours post-stroke, then every 3 days for four more doses) improved neurological function at 2 and 12 mg/kg — significant from day 14 through day 56 — while 18 mg/kg produced no significant benefit, and a modeled optimal dose of roughly 3.75 mg/kg was proposed [4]. That result is non-monotonic: higher was not better. It is a clean rebuttal to community "loading" rationales, and it is preclinical. ## Angiogenesis and its safety implications thymosin beta-4 promotes endothelial migration and new-vessel formation, and angiogenesis is one of the repair processes credited to it across models [5]. The same property is the basis of the principal safety caveat. thymosin beta-4 is overexpressed in several cancers and is implicated in metastasis and tumor angiogenesis; the pro-migratory, pro-angiogenic activity that aids repair could, in theory, support tumor progression. This is the repair-versus-risk duality, and it is an unresolved signal rather than a demonstrated human effect. ## Anti-inflammatory and anti-fibrotic signaling Reviews report that thymosin beta-4 limits inflammation and decreases myofibroblast number, reducing scar formation after injury [5]. Mechanistic in vitro work attributes part of this to suppression of NF-kappaB and IL-8 signaling. These are mechanistic and preclinical findings for the full-length protein; they have not been established for the Ac-LKKTETQ fragment in humans. --- A chromatic-split scope reading of the TB-500 record — the Ac-LKKTETQ fragment held on one channel and full-length thymosin beta-4 on the other so the two are never mistaken for one trace, the FDA 503A standing read before anything else, with no clinic behind the scope and nothing here dispensed or sold.